ライフサイエンスコーパス: vaccination

1 and vaccinia virus (previous DryVax smallpox vaccination).

2 disappeared within 2 months after the final vaccination.

3 in the bone marrow for several months after vaccination.

4 for generating high-avidity T cells through vaccination.

5 8 participants in the group after the second vaccination.

6 derlying differential responses to influenza vaccination.

7 5 new SCCs and 0.92 new BCCs per year before vaccination.

8 urs, and strengthening community support for vaccination.

9 or in any organ 1 month following the 14(th) vaccination.

10 mary CD4(+) T cell response during NS4B-P38G vaccination.

11 secrete protective antibodies within days of vaccination.

12 to nonvaccinia OPXV infections from smallpox vaccination.

13 e used as an immunostimulant for microneedle vaccination.

14 ccine candidates in mice and compared to DNA vaccination.

15 hlighted by WHO to inform potential maternal vaccination.

16 tection and risk associated with RTS,S/AS01E vaccination.

17 by descendants of NVT clones present before vaccination.

18 e T cells of high functional avidity through vaccination.

19 all adverse events in the 28 days after each vaccination.

20 2 new SCCs and 2.25 new BCCs per year before vaccination.

21 ady higher than those of young adults before vaccination.

22 siRNA, to treat localised disease or provide vaccination.

23 anding repertoire responses to infection and vaccination.

24 sponse to diphtheria toxoid and pneumococcal vaccination.

25 HCDR3-binder bnAbs via sequential HIV-1 Env vaccination.

26 cells that may affect immune responses upon vaccination.

27 tly higher than 2 weeks after the last RV144 vaccination.

28 ut these can be easily perturbed, such as by vaccination.

29 exual males in settings with female-only HPV vaccination.

30 hese, 22% were in the group age-eligible for vaccination.

31 n broaden humoral responses following rabies vaccination.

32 tential to tailor the immune response to DNA vaccination.

33 on of sterile immunity during whole-organism vaccination.

34 c symmetry has ushered in a new era in HIV-1 vaccination.

35 ples from a country with universal rotavirus vaccination.

36 ving personal belief exemptions of childhood vaccination.

37 missed opportunities to initiate hepatitis B vaccination.

38 dosing schemes have driven down the cost of vaccination.

39 ctions has been a long-sought-after goal for vaccination.

40 nses at early time points after infection or vaccination.

41 lation-level impact in males from female HPV vaccination.

42 1 + 1 schedule) delivered with other routine vaccinations.

43 inate P falciparum before the first and last vaccinations.

44 ll children had a history of prior influenza vaccinations.

45 uded only participants who received all five vaccinations.

46 d compared with 2 weeks after the last RV144 vaccination (14069 vs 999; P < .001).

47 1 month after the third vaccination, 93% (n=139/149) to 100% (n=48/48) of vaccin

48 nic adjuvant formulation 09, render low-dose vaccination a feasible and promising approach for genera

49 tion at GTEN sites, 16% met criteria for MMR vaccination according to the provider's assessment, but

50 accine protection with increasing time since vaccination across influenza types/subtypes.

51 In addition to rotavirus vaccination, actions to improve nutrition status, sanita

52 vider registeries) reporting on yellow fever vaccination activities between May 1, 1939, and Oct 29,

53 ratio, 1.04; 95% CI, 0.68-1.58) or influenza vaccination (adjusted hazard ratio, 1.10; 95% CI, 1.00-1

54 identified individual data on herpes zoster vaccinations administered and consultations for herpes z

55 tionwide registers, we linked information on vaccination, adverse pregnancy outcomes, and potential c

56 Our results demonstrate that incremental vaccination against a single chemical species within a m

57 Vaccination against all serotypes is necessary to protec

58 Maternal vaccination against group B Streptococcus (GBS) might pr

59 ation of America (MGFA) class II-IV disease, vaccination against Neisseria meningitides, and previous

60 ch-up (AGW = 9.9, CC = 678) and routine-only vaccination (AGW = 9.9, CC = 677), thus providing simila

61 herd immunity above that achieved by direct vaccination alone but also increases the opportunity for

62 Natural infection and vaccination also induced serum-neutralizing antibodies t

63 s of the areas that could be prioritised for vaccination, although other constraints such as vaccine

64 ociation between influenza VE and time since vaccination among patients >/=9 years old with medically

65 emic reactogenicity in the 7 days after each vaccination and all adverse events in the 28 days after

66 ounders, we found no association between BCG vaccination and asthma.

67 ation between bacillus Calmette-Guerin (BCG) vaccination and childhood asthma in a birth cohort using

68 ributed in part to the cessation of smallpox vaccination and concomitant waning of population-level i

69 Decades of increasing vaccination and development have led to dramatic decline

70 te the introduction of universal hepatitis B vaccination and effective antiviral therapy, the estimat

71 splantation) or enhance T-cell survival (eg, vaccination and immune deficiency).

72 s in the vaccine group 1 day after the first vaccination and in and two (2%) of 98 participants in th

73 example of measles, mumps, and rubella (MMR) vaccination and measles.

74 d macaque cross-reactive V3 NAbs elicited by vaccination and prototypic V3 NAbs derived from natural

75 ngland in view of differences and changes in vaccination and screening uptake by ethnicity in England

76 d vaccination status defined by days between vaccination and symptom onset as the predictor.

77 a-like illness between 14 days or more after vaccination and the end of the influenza season.

78 participants who received at least one trial vaccination) and the immunogenicity analyses were based

79 nomic variation, birth cohort effects, prior vaccination, and epidemic period.

80 ion, accelerated tissue formation, effective vaccination, and nanotherapeutics for targeted disease t

81 group subpopulations can be prioritized for vaccination, and the vaccine interventions are cost savi

82 verse events occurred in the first day after vaccination, and were mild to moderate in intensity, of

83 d adaptive anti-PDAC immunity when used in a vaccination approach, direct tumor injection or intraven

84 ter understand the response to infection and vaccination, as well as the dysregulation that occurs in

85 Vaccination at 27-36 weeks gestation was more effective

86 RC 320 participants were assigned to receive vaccinations at 0, 4, and 8 weeks via single-dose needle

87 orphology can be detected for 10 years after vaccination/BrdU administration, indicating that plasma

88 sed initially on generating demand for polio vaccination but later expanded its messaging to promote

89 n against infections can be achieved through vaccination, but the optimal vaccination schedule in lun

90 high for the three IPV-Al vaccines after two vaccinations, but was higher after three vaccinations (i

91 s study suggest that efficacy of oral rabies vaccination by aerial delivery is associated with landsc

92 mRNA vaccination by needle-free intradermal or intramuscular

93 letion of enrolment, we implemented an mOPV2 vaccination campaign that targeted 40% of children young

94 e risk of Sabin 2 transmission after a polio vaccination campaign with a monovalent type 2 oral polio

95 ake recommendations to help improve reactive vaccination campaigns against cholera, and discuss the i

96 However, cholera vaccination campaigns have often excluded pregnant women

97 Despite implementation of mass measles vaccination campaigns, measles outbreaks continue to occ

98 were conducted in conjunction with MenB-FHbp vaccination campaigns.

99 uld support evidence-based planning for mass vaccination campaigns.

100 disease, vaccination is recommended; whether vaccination can protect by opsonophagocytic activity in

101 radius was found to be highly dependent upon vaccination capacity for all management objectives.

102 During the acute response to influenza vaccination, CD19(pos), CD19(low), and CD19(neg) ASCs se

103 Data from animal studies and a ring vaccination clinical trial conducted in Guinea during th

104 ibition (HAI) titers, more than 8-month post-vaccination compared to influenza VLPs without CCL28 or

105 tly higher at day 28 after microneedle patch vaccination compared with placebo (all p<0.0001) and wer

106 Similarly, the increasing trend in child vaccination completion during the pre-epidemic period wa

107 dy response compared with standard influenza vaccination consisting of a single dose.

108 It also suggests that the rate of vaccination contagion may be even more important than th

109 High vaccination coverage and control measures likely limited

110 sources, including personnel, for increasing vaccination coverage and improved performance monitoring

111 ntion were used to simulate county-level MMR vaccination coverage in children (age 2-11 years) in the

112 for self-administration can expand influenza vaccination coverage in developing countries.

113 V infection is not well known, while the HPV vaccination coverage is low in the United States.

114 stem utilization with influenza illness, and vaccination coverage through active community-based surv

115 Among vaccine-eligible men, the HPV vaccination coverage was 10.7% (95% CI, 7.8%-14.6%).

116 population density, forest cover and routine vaccination coverage were the strongest predictors of po

117 In 12 zones with low vaccination coverage within Kinshasa Province, Democrati

118 to consider possible explanations including vaccination coverage, changes in screening for cervical

119 4-month-olds in municipalities with <90% MMR vaccination coverage.

120 nsmission as long as they do not attain high vaccination coverage.

121 ographic, sexual behavior, and self-reported vaccination data from females 14-34 years old.

122 accine have supported that influenza A(H1N1) vaccination does not increase the risk for major pregnan

123 Influenza vaccination during 2013-14 influenza season attenuated a

124 Some women will have inadvertent exposure to vaccination during early pregnancy, but few data exist r

125 vestigated the association between influenza vaccination during pregnancy and ASD.

126 Vaccination during pregnancy is an effective way to prot

127 Neither vaccination during pregnancy or use of the larvicide pyr

128 Quadrivalent HPV vaccination during pregnancy was not associated with a s

129 However, similar to the effect of Tdap vaccination during pregnancy, immune responses of later-

130 thers and 45 231 (23%) received an influenza vaccination during pregnancy.

131 ctive at preventing pertussis in infant than vaccination during the second trimester.

132 risons revealed substantial increases in HPV vaccination during this time period, and more modest red

133 years) after high-risk groups for influenza vaccination during times of limited vaccine supplies.

134 Prior vaccination effects were interpreted within the ADH fram

135 While causing little skin irritation, vaccination efficacy of BCG-MNAs was comparable to that

136 l polio vaccine (OPV) has enabled world-wide vaccination efforts, which resulted in nearly complete c

137 in incapable of being neutralized by current vaccination efforts.

138 Thus, we postulate that vaccination establishes clonal relatives of GCTfh within

139 Patients who received CMV-ATCT-DC vaccination experienced a significant increase in the ov

140 Annual vaccination for healthcare workers and other high-risk g

141 On Sept 1, 2008, Scotland launched routine vaccination for human papillomavirus (HPV) types 16 and

142 erent RSV immunisation strategies (targeting vaccination for infants, or pregnant women, or prophylac

143 ved decreasing VE with increasing time since vaccination for influenza A(H3N2) (p=0.004), influenza A

144 ditional boosts, given 6-8 years since RV144 vaccination, for safety and immunogenicity, at weeks 0 a

145 or without ALVAC-HIV 6-8 years after initial vaccination generated higher humoral responses than afte

146 H3N2 influenza virus when compared to other vaccination groups.

147 adjudication pathology panel were masked to vaccination groups.

148 ctive level in both the repeated- and single-vaccination groups.

149 Those animals that received only vaginal vaccinations had identical IgG but superior IgA response

150 -40) who have a combination of screening and vaccination history, and weighted to estimate the popula

151 two vaccinations, but was higher after three vaccinations (ie, after completion of the expanded progr

152 model, absence of gammadelta T cells during vaccination impaired protective CD8 T cell responses and

153 an antibodies following natural infection or vaccination.IMPORTANCE The four serotypes of dengue viru

154 V13 before and at 1, 12, and 24 months after vaccination in 1006 PCV13 recipients and 1005 controls w

155 vidence base for continuing annual influenza vaccination in adults.

156 ong vaccinated individuals from day 10 after vaccination in both randomised and non-randomised cluste

157 the study of germinal center reactions after vaccination in children.

158 study suggests that the introduction of HPV vaccination in England will initially widen a pre-existi

159 tween the cross-reactive V3 NAbs elicited by vaccination in macaques and natural infections in humans

160 Our results suggest that adjuvanted vaccination in populations where PEM is endemic may be o

161 Maternal influenza vaccination in the second or third trimester was not ass

162 children whose mothers received an influenza vaccination in their first trimester, but the associatio

163 geometric mean titres detected 1-month post-vaccination in Vi-TT vaccinees.

164 sures of vaccine responsiveness and improved vaccinations in this at-risk group are needed.

165 iminished innate immune responses, vDeltaK1L vaccination induced a protective VACV-specific CD8(+) T

166 Vaccination induced strong mE6 and mE7 CD8(+) T cell res

167 ay differentially affect cross-reactivity of vaccination-induced H3-specific hemagglutination inhibit

168 Universal childhood vaccination is a potential solution to reduce seasonal i

169 Vaccination is an important and cost-effective disease p

170 Routine childhood vaccination is declining in some regions of the United S

171 old increased risk of meningococcal disease, vaccination is recommended; whether vaccination can prot

172 er strategy 5 weeks after standard influenza vaccination is safe and effective and induces an increas

173 l-mediated immunity responses to hepatitis B vaccination is still controversial.

174 Despite mass vaccination, it remains a leading cause of death in chil

175 asing due to the absence of routine smallpox vaccination leading to a higher proportion of naive popu

176 ention of infections, adherence with routine vaccinations, management of comorbid conditions, and adh

177 volvement of the immune system suggests that vaccination may also play a role.

178 For persons with asthma, influenza vaccination may be effective in both reducing influenza

179 Protection by vaccination may not be sustained in the second year of l

180 ing treated with eculizumab and suggest that vaccination may provide better protection against mening

181 uggested that Bacillus Calmette-Guerin (BCG) vaccination may reduce the risk of allergic diseases, in

182 These data suggest that DNA vaccination merits further investigation as a potential

183 We hypothesized that additional vaccinations might augment immune correlates of protecti

184 ent of effective B cell immunity elicited by vaccination, not just against HIV-1.

185 Oral rabies vaccination of foxes is an effective method for controll

186 Routine vaccination of HIV-infected persons with a quadrivalent

187 Vaccination of mice with peptides containing the 13B5 ta

188 Quadrivalent HPV vaccination of MSM via GUM clinics is likely to be an ef

189 otection should be considered when assessing vaccination of older age groups.

190 vaccine was recommended in 2006 for routine vaccination of US females aged 11-12 years.

191 in 47 clusters randomly assigned to delayed vaccination (of whom 3096 were eligible, 2539 consented,

192 n 51 clusters randomly assigned to immediate vaccination (of whom 3232 were eligible, 2151 consented,

193 The effect of vaccination on emergency department (ED) utilization for

194 of the study, none of which were related to vaccination (one in the Vi-TT group and three in the Vi-

195 accine, we demonstrate the advantage of skin vaccination over intramuscular delivery of a two-fold hi

196 robust IgG1 and IgG2a antibodies after three vaccinations (P < 0.001).

197 After intradermal, but not intramuscular, vaccination, participants with AD with S aureus coloniza

198 SVDeltaG pseudovirions serve as a successful vaccination platform in a rodent model of Ebola virus di

199 ccines through assessments of new adjuvants, vaccination platforms, and antigens.

200 The added benefit of mine-targeted vaccination primarily reflected the disproportionate dem

201 The vaccination problem is a related question that is much m

202 usceptibility in response to demographic and vaccination processes emphasizes the importance of progr

203 changes in response to both demographic and vaccination processes.

204 per 100,000 (IQR, 260-370), while postnatal vaccination produced a minimal reduction, with an incide

205 bination mass drug administration and a mass vaccination program approach to eliminate malaria from g

206 V types and non-4vHPV types suggest that the vaccination program has had an impact on the prevalence

207 and health impact despite a long established vaccination programme and approved antivirals.

208 this end, the country enhanced its mandatory vaccination programs and achieved vaccination rates repo

209 Targeted vaccination programs could be used to vaccinate habituat

210 an significantly reduce the effectiveness of vaccination programs.

211 oups, timing, and cost of national influenza vaccination programs.

212 PEM is endemic may be one strategy to boost vaccination-promoted immunity and improve outcomes assoc

213 These data demonstrate that influenza vaccination promotes the prevalence of relevant immune c

214 nd potentially transformative strategies for vaccination, protein replacement therapy, and genome edi

215 We discovered that not only does vaccination provide high levels of protection against le

216 However, the optimal vaccination radius was found to be highly dependent upon

217 mandatory vaccination programs and achieved vaccination rates reported above 95% by 2008.

218 oportionately benefiting subgroups with high vaccination rates.

219 By linkage to vaccination records we ascertained prevalence by birth c

220 ber 2015 by conducting interviews, reviewing vaccination records, and observing activities.

221 serotypes tested following a homologous FMDV vaccination regime.

222 Similar vaccination regimens have been used successfully to indu

223 tainty exists as to whether low-risk elderly vaccination remains cost-effective, driven by the choice

224 Although high-risk vaccination remains cost-effective, substantial uncertai

225 Preventing malaria infection through vaccination requires preventing every sporozoite inocula

226 signaling were associated with an effective vaccination response in young adults.

227 second- rather than third-trimester maternal vaccination results in higher birth anti-pertussis toxin

228 After vaccination, rVSV viremia occurred frequently but was tr

229 chieved through vaccination, but the optimal vaccination schedule in lung transplant recipients is un

230 ent best practice statements for hepatitis B vaccination, screening, and linkage to care.

231 beneficiaries who had received pneumococcal vaccination (secondary analysis).

232 ile few participants completed the full MenB vaccination series, limiting analytic power, these data

233 hain in 23 health facilities and 36 outreach vaccination sessions in 8 districts and cities of Bangla

234 nized with S aureus, intramuscular influenza vaccination should be given preference in these patients

235 igher functional avidity induced by low-dose vaccinations showed higher cytokine release per cell and

236 Prepregnancy Tdap vaccination significantly increases maternal antibody co

237 ing that widespread use of childhood measles vaccination since 1963 resulted in a decrease in average

238 irmed influenza infection as the outcome and vaccination status defined by days between vaccination a

239 per week was estimated according to district vaccination status.

240 e ascertained prevalence by birth cohort and vaccination status.

241 red in patients with parotitis regardless of vaccination status.

242 ctiveness of alternative maternally targeted vaccination strategies (antenatal delivery vs. postnatal

243 viously used in the United Kingdom to inform vaccination strategies for influenza, with extensions to

244 t show promise for informing therapeutic and vaccination strategies for vulnerable patients.

245 New vaccination strategies incorporating NA, including PIV5-

246 tant implications for the design of maternal vaccination strategies that could synergize with ART dur

247 Within this context, we discuss vaccination strategies to elicit broad and potent immune

248 Our findings suggest that different vaccination strategies will be required to optimize prot

249 the development of different candidates and vaccination strategies.

250 flexible context-specific dose regimens and vaccination strategies.

251 velopment of improved influenza vaccines and vaccination strategies.

252 INTERPRETATION: The results show that a ring vaccination strategy can be rapidly and safely implement

253 ous prime-boost may provide a more effective vaccination strategy to broaden the antibody responses t

254 Vaccinations studied comprised Bacillus Calmette-Guerin

255 ntially the design of attenuated viruses for vaccination studies.IMPORTANCE SFTS phlebovirus (SFTSV)

256 an loss does not influence immunogenicity or vaccination success.IMPORTANCE The West African Ebola vi

257 nt reduction in HPV prevalence 4 years after vaccination suggests that the bivalent HPV-16/18 vaccine

258 y exhibit heart involvement, and there is no vaccination that protects against the disease.

259 rritation, in marked contrast to intradermal vaccination that provoked severe inflammation and bruise

260 Finally, after influenza vaccination, the proportion of influenza-specific CD4(+)

261 By 1 month after vaccination, the vaccines had elicited immune responses

262 cells following influenza virus infection or vaccination, they failed to support activation of naive

263 At pound48 a dose, offering vaccination to all MSM up to age 40 is likely to be cost

264 ere collected before the influenza season or vaccination to assess antibody and T-cell responses.

265 th impact and cost-effectiveness of offering vaccination to MSM who visit genitourinary medicine (GUM

266 anagement strategies, and support the use of vaccination to reduce bTB infection in badgers.

267 e did an open-label, cluster-randomised ring vaccination trial (Ebola ca Suffit!) in the communities

268 It highlights the shortcomings of the RV144 vaccination trial [ALVAC-HIV (vCP1521) and AIDSVAX B/E]

269 ng medical care and of 2.4 times increase in vaccination uptake.

270 Prime-boost vaccination via sequential s.c. and i.m. administration

271 e findings highlight the efficacy of mucosal vaccination via this attenuated strain and will guide it

272 during a measles epidemic in 2013-2014, MMR vaccination was also offered to 6-14-month-olds in munic

273 Influenza vaccination was associated with a reduction in the odds

274 Among the 1592 children, early measles vaccination was not associated with a higher risk of the

275 specific analyses, first-trimester influenza vaccination was the only period associated with increase

276 Eleven days after vaccination, we observed an approximately 70-fold expans

277 Negative effects of prior vaccination were pronounced and statistically significan

278 Vaccinations were given intramuscularly on days 1 and 29

279 ecific CD8(+)CD57(+) senescent T cells after vaccination, which were already higher than those of you

280 boosted group as well, indicating that skin vaccination with 4M2e-tFliC facilitated a long-term anti

281 After vaccination with a multivalent GI.1 and GII.4c norovirus

282 developing medical countermeasures and that vaccination with a mutant lacking expression of the prot

283 aper on the preventive effect of tolerogenic vaccination with a strong agonist insulin mimetope in ty

284 Vaccination with BCG-MNA caused no overt skin irritation

285 Vaccination with both the VC2-EHV-1-gD vaccine and the c

286 tion; however, only passive immunization, or vaccination with inactive SpeA, resulted in high-titer S

287 We hypothesized that vaccination with neoantigens can both expand pre-existin

288 Vaccination with PP7-AIP1S elicited AIP1-specific antibo

289 greatly enhances leptospiral protection over vaccination with single parent domains.

290 ses elicited by prior infection with DENV or vaccination with tetravalent dengue attenuated vaccines

291 ding prompted us to test the hypothesis that vaccination with the batA mutant strain elicits protecti

292 led that the protective immunity afforded by vaccination with the batA mutant strain is predominantly

293 was reported in Guinea, and in response ring vaccination with the unlicensed rVSV-ZEBOV vaccine was i

294 HV-1-reactive IgG subtypes demonstrated that vaccination with the VC2-EHV-1-gD vaccine stimulated rob

295 Following vaccination with trivalent oral polio vaccine (tOPV) at

296 Vaccination with VC2-EHV-1-gD stimulated strong cellular

297 en </=33 years had been age-eligible for HPV vaccination, with 3-dose uptake across age cohorts being

298 e fusion protein.IMPORTANCE Due to lapses in vaccination worldwide that have caused localized outbrea

299 There are windows of opportunity in which vaccination would be beneficial, but to date, no vaccine

300 Before vaccination, Zaire Ebola virus (ZEBOV)-glycoprotein (GP)